International


CONNECTING SCIENCE, BRIDGING INNOVATION


Maximum capacity, minimal footprint: Rethinking autoclave design for modern research labs


maintaining a compact footprint - typically no wider or deeper than one metre. This enables tall loads to be processed efficiently while reducing energy, water use, acquisition costs, and improving throughput.


Among Priorclave’s top-loading offerings, the EV200-SMART stands out with a vertically oriented 200-litre pressure vessel. Engineered for demanding research environments, this autoclave integrates advanced sterilisation features, including: Automatic timed free-steaming; Forced air cooling; Multi-stage pre-cycle vacuum with interspersed heating; Vacuum-assisted drying ; Pulsed free-steaming to enhance vacuum efficiency.


Laboratories often assume high-capacity autoclaves must be large, front-loading units that dominate floor space. For many research applications, this is unnecessary. The main requirement is vertical clearance for tall vessels, not expansive horizontal volume.


Priorclave, a UK-based manufacturer renowned for precision-engineered autoclaves, has addressed this need with its top-loading designs. These units offer substantial chamber capacity while


These features ensure thorough sterilisation of complex and porous loads, making the EV200- SMART ideal for microbiology, molecular biology, and bioprocessing workflows.


The EV200-SMART’s pressure vessel is insurance-approved with a 10-year warranty. Thermal and pressure interlocks prevent access above 80°C or 0.2 bar.


All Priorclave autoclaves are equipped with the proprietary Tactrol®


3 controller, offering


intuitive, glove-friendly operation and fully programmable cycles. The unit’s epoxy-coated panels and frame are treated with a long-


Pre-aligned collimators and expanders for large optic systems


Optics


Autocalves


Updated range of recirculating chillers


Chillers


lasting antimicrobial agent effective against all known bacteria and fungi, including MRSA - supporting aseptic conditions and simplifying cleaning protocols.


Recognising that not all labs require a 200-litre chamber, Priorclave offers the EV-SMART series in 100-litre and 150-litre models as well. For facilities with less complex sterilisation needs, a Basic edition is also available - omitting vacuum features while retaining core performance and safety standards.


Priorclave is one of the few autoclave manufacturers globally to maintain complete control over its supply chain.


All principal components are fabricated in-house at their London facility, including pressure vessels produced using a proprietary seam welding system. This commitment to craftsmanship ensures long- term durability and consistent performance - hallmarks of the brand’s reputation.


Priorclave continues to set the standard for autoclave innovation - delivering high- capacity sterilisation without compromising space, safety, or sustainability.


More information online: ilmt.co/PL/jYeO 65969pr@reply-direct.com


An updated range comprising eight laboratory recirculating chillers by Labtech is available from Analytix that have excellent cooling capabilities and offer cooling power from 240 watts to 9000 watts.


Specifically designed for analytical, medical and industrial use they provide temperatures ranging from -20°C to 35°C so are suitable for all cooling applications.


The latest design of the chiller range has concentrated on reducing the noise level that then has an impact on noise in the laboratory. The smaller portable chillers are suitable to be placed on a laboratory bench plus the whole range can be floor standing with casters for easy transportation inside the laboratory.


More information online: ilmt.co/PL/JoQZ 66472pr@reply-direct.com


New AAV supplement enhances gene therapy production


large optical systems. High performance is achieved through a novel mounting technique, delivering a zero expansion parabolic mirror better than lambda /10.


Optical Surfaces Ltd has introduced a novel approach to large-diameter optical systems with its pre-aligned beam collimator and beam expander modules. Traditional solutions for long focal length or large-diameter optics often involve bulky, heavy, and costly reflective systems. Optical Surfaces’ modular, lightweight kits overcome these limitations while maintaining precision and stability.


The company’s pre-aligned beam collimator kits feature a new kinematic mounting system, enabling faster, more accurate, and highly reproducible assembly of


Beam expanders follow a similar concept. While enclosed pre-aligned optical systems work for diameters up to 200 mm, larger systems become impractical due to size and weight. Optical Surfaces’ pre-aligned beam expander modules, suitable for optics up to 500 mm, include fully mounted primary and secondary mirrors that come pre-set and aligned. This eliminates the need for complex five-degree-of-freedom setups, reducing installation from days or weeks to just a few hours.


By combining pre-alignment with kinematic mounting, Optical Surfaces provides researchers and engineers with a practical, cost-effective solution for building large optical systems quickly without compromising precision.


More information online: ilmt.co/PL/BZRR 65852pr@reply-direct.com


Ajinomoto CELLiST Korea, part of the Ajinomoto Group, has launched CELLiST™ AAV Production Supplement 1, a new culture medium additive designed to enhance viral vector productivity in gene therapy manufacturing.


Developed in collaboration with U.S.-based Forge Biologics, a leading CDMO for adeno- associated virus (AAV) development, the supplement has demonstrated a 1.3–2× increase in AAV production compared with standard culture methods. These results were highlighted at the Japan Society of Gene and Cell Therapy (JSGCT) in July 2025.


With the global gene therapy market expected to grow from US$7 billion in 2022 to US$46 billion by 2030, improving viral vector yields while reducing production costs is a critical challenge. CELLiST™ AAV Production Supplement 1 addresses this by combining Ajinomoto’s formulation expertise with Forge Biologics’ large-scale manufacturing know-how, supporting scalable, efficient, and reliable production.


Ajinomoto CELLiST Korea has over 30 years of experience in high-performance cell culture media, optimised for CHO and HEK293 cell lines. The company will use the new supplement to support customers across


CE-marked genetic test for Type 1 Diabetes risk


Randox Laboratories has received CE marking for its pioneering genetic test for Type 1 Diabetes (T1D) risk – the first of its kind globally. The approval allows deployment across Europe and provides clinicians with a powerful tool to identify individuals at high risk of developing T1D before symptoms appear.


The test, developed in collaboration with the University of Exeter, uses up to ten diabetes-


associated genetic variants to generate a rapid, accurate risk score. This enables early referral for confirmatory antibody testing and monitoring, supporting timely intervention with emerging therapies designed to delay or prevent disease onset, such as teplizumab.


Beyond risk assessment, the biochip can aid diagnosis by distinguishing Type 1 from Type 2 diabetes, helping clinicians make better-


informed treatment decisions. T1D affects more than eight million people worldwide, with many cases occurring in individuals without a family history, making early detection challenging under current models.


The CE-marked biochip offers a scalable, cost- effective foundation for national screening initiatives, allowing healthcare systems to focus resources on those most likely to


Reagents


Asia seeking to boost viral vector output and streamline gene therapy manufacturing.


“We are excited to offer CELLiST™ AAV Production Supplement 1 to gene therapy developers,” said President Sugiyama of Ajinomoto CELLiST Korea. “Our aim is to help labs achieve higher productivity, better scalability, and more consistent results in their viral vector production.”


Ajinomoto CELLiST Korea continues to apply AminoScience-based innovations to accelerate biopharmaceutical manufacturing, from monoclonal antibodies to next- generation gene therapies.


More information online: ilmt.co/PL/4lzl 66437pr@reply-direct.com


Diagnostics


develop the disease, while screening out low-risk individuals. By combining precision genetics with practical clinical application, Randox is setting a new standard in diabetes diagnosis, risk stratification, and early intervention.


More information online: ilmt.co/PL/4ly9 66578pr@reply-direct.com


58


INTERNATIONAL LABMATE - FEBRUARY 2026


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84